Duke logo

HSP90 for Imaging Malignancies - Clinical Trial

What is the Purpose of this Study?

We are doing this study to see if the study drug, HS-196, is safe and to see if there are any side effects that people may experience while taking it.

HS-196 is a drug which marks cancer cells and it may help doctors see the cancer during and after surgery.

What is the Condition Being Studied?

Breast, Prostate, and Pancreatic Cancer Imaging

Who Can Participate in the Study?

Adults who are having surgery for:
- Prostate cancer
- pancreatic cancer
- breast cancer

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Be given the study drug, HS-196 by injection up to 36 hours before surgery
- Allow us to use your tissue that is removed for research
- Give blood on the day of the injection, day after injection, 1 week following injection, and 1 month following injection

Study Details

Full Title
A Phase I Study of HS-196, an HSP90 Inhibitor-Linked Near Infrared Probe for Detection of Solid Malignancies
Principal Investigator
Protocol Number
IRB:PRO00082272
NCT:NCT03333031
Phase
Phase I
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698